OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
09653058

Seegene Inc

Biotechnology & Medical ResearchVerified

Seegene Inc maintains a strong liquidity position, with a current ratio of 4.68 and cash and equivalents amounting to KRW 225.57 billion, which is well above the industry median. The company's debt-to-equity ratio is 0.13, indicating a conservative capital structure with limited leverage. Profitability metrics show a return on equity (ROE) of 4.75% and a return on assets (ROA) of 3.91%, which are in line with the industry's preferred metrics. The company's operating income of KRW 26.15 billion and net income of KRW 48.27 billion reflect a healthy margin profile, although the gross profit margin of 64.1% suggests room for improvement in cost management. Geographically, Seegene's revenue is concentrated in South Korea, with a significant portion of its sales derived from domestic operations. The company has a limited presence in international markets, which may expose it to regional economic fluctuations and regulatory changes. The company's growth trajectory is positive, with a revenue of KRW 474.23 billion in the latest reporting period. While no specific growth rate is provided, the operating cash flow of KRW 149.33 billion and free cash flow of KRW 40.93 billion indicate strong cash generation capabilities. The capital expenditure of KRW -40.47 billion suggests a reduction in investment, which may signal a shift in strategic focus. Risk factors for Seegene include the potential for dilution, although the risk is currently assessed as low. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is minimal based on the current share structure. The risk assessment also indicates a low liquidity risk, supported by the company's strong cash reserves and low debt levels. Recent events, including analyst estimates and recommendations, suggest a generally positive outlook for Seegene. The mean price target of KRW 39,500 and the median price target of KRW 39,500 reflect a consensus among analysts. The mean recommendation of 1.50, with one strong-buy and one buy rating, indicates a favorable sentiment towards the stock.

30-day price · 096530(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanySeegene Inc
Ticker096530.KQ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Seegene Inc is a South Korean biotechnology company that develops and commercializes molecular diagnostic solutions, primarily for infectious diseases and cancer, generating revenue through the sale of diagnostic kits and related services.

Classification. Seegene is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

Seegene Inc maintains a strong liquidity position, with a current ratio of 4.68 and cash and equivalents amounting to KRW 225.57 billion, which is well above the industry median. The company's debt-to-equity ratio is 0.13, indicating a conservative capital structure with limited leverage. Profitability metrics show a return on equity (ROE) of 4.75% and a return on assets (ROA) of 3.91%, which are in line with the industry's preferred metrics. The company's operating income of KRW 26.15 billion and net income of KRW 48.27 billion reflect a healthy margin profile, although the gross profit margin of 64.1% suggests room for improvement in cost management. Geographically, Seegene's revenue is concentrated in South Korea, with a significant portion of its sales derived from domestic operations. The company has a limited presence in international markets, which may expose it to regional economic fluctuations and regulatory changes. The company's growth trajectory is positive, with a revenue of KRW 474.23 billion in the latest reporting period. While no specific growth rate is provided, the operating cash flow of KRW 149.33 billion and free cash flow of KRW 40.93 billion indicate strong cash generation capabilities. The capital expenditure of KRW -40.47 billion suggests a reduction in investment, which may signal a shift in strategic focus. Risk factors for Seegene include the potential for dilution, although the risk is currently assessed as low. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is minimal based on the current share structure. The risk assessment also indicates a low liquidity risk, supported by the company's strong cash reserves and low debt levels. Recent events, including analyst estimates and recommendations, suggest a generally positive outlook for Seegene. The mean price target of KRW 39,500 and the median price target of KRW 39,500 reflect a consensus among analysts. The mean recommendation of 1.50, with one strong-buy and one buy rating, indicates a favorable sentiment towards the stock.
Key takeaways
  • Seegene Inc has a strong liquidity position with a current ratio of 4.68 and significant cash reserves.
  • The company's profitability metrics, including ROE of 4.75% and ROA of 3.91%, are in line with industry standards.
  • Revenue is heavily concentrated in South Korea, which may increase exposure to regional economic and regulatory risks.
  • Analysts have a generally positive outlook, with a mean price target of KRW 39,500 and a mean recommendation of 1.50.
  • The company's capital structure is conservative, with a low debt-to-equity ratio of 0.13 and minimal dilution risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$474.23B
Gross profit$303.86B
Operating income$26.15B
Net income$48.27B
R&D
SG&A
D&A
SBC
Operating cash flow$149.33B
CapEx-$40.47B
Free cash flow$40.93B
Total assets$1.24T
Total liabilities$220.35B
Total equity$1.02T
Cash & equivalents$225.57B
Long-term debt$129.93B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.02T
Net cash$95.64B
Current ratio4.7
Debt/Equity0.1
ROA3.9%
ROE4.8%
Cash conversion3.1%
CapEx/Revenue-8.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric096530Activity
Op margin5.5%-2.9% medp25 -218.9% · p75 9.6%above median
Net margin10.2%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin64.1%47.8% medp25 27.6% · p75 68.9%above median
CapEx / revenue-8.5%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity13.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Observations
IR observations
Mean price target39,500.00 KRW
Median price target39,500.00 KRW
High price target44,000.00 KRW
Low price target35,000.00 KRW
Mean recommendation1.50 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate1,116.18 KRW
Last actual EPS1,046.72 KRW
Source: analysis-pipeline (hybrid)Generated: 2026-05-20 12:23 UTCJob: d1faca09